Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 3 art units • 9 examiners • 0 of 10 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
BEIGENE, LTD. has 11 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are concentrated within 4 distinct art units, suggesting that the company's current prosecution is focused on a few specific technical fields. The company interacts with 10 distinct examiners, which indicates little examiner overlap across the 11 pending office actions. This distribution requires the company to manage the 10 individual examiner relationships simultaneously.
TOWNSLEY, SARA ELIZABETH is the busiest examiner for the portfolio, managing 2 pending office actions. The remaining pending office actions are each handled by a different examiner. While the 4 distinct art units provide technical grouping, the variety of 10 distinct examiners means that practitioners must account for different individual perspectives. Successfully navigating these 11 pending office actions will require a strategy that balances the standards of the 4 distinct art units with the preferences of 10 different examiners. The high ratio of examiners to actions suggests a decentralized prosecution environment.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (10%) |
| §102 only | 1 (10%) |
| §112 only | 2 (20%) |
| Double-patenting only | 1 (10%) |
| Double-patenting + other | 2 (20%) |
| Multi-statute (no §101) | 3 (30%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TOWNSLEY, SARA ELIZABETH | 2 | 25.5% | +49.1% |
| ARCORIA, PAUL JOSEPH | 1 | — | — |
| CHICKS, ASHLI ARIANA | 1 | 60.6% | +50.3% |
| CHEN, PO-CHIH | 1 | 74.2% | +14.8% |
| SHUPE, ELIZABETH A | 1 | 66.2% | +44.2% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.3% |
| ALLEN, MARIANNE P | 1 | 60.1% | +18.2% |
| SEITZ, ANTHONY JOSEPH | 1 | 68.3% | +27.0% |
| SHOWALTER, ALEXANDER KEITH | 1 | 54.4% | +26.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263448 | METHODS OF TREATING CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION USING BTK INHIBITORS | SEITZ, ANTHONY JOSEPH | 29d |
| 18897194 | KAT6 Inhibitors | CHICKS, ASHLI ARIANA | — |
| 18748855 | SOLID FORMS OF A TYK2 INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | TOWNSLEY, SARA ELIZABETH | — |
| 18678898 | Compounds for the Degradation of EGFR Kinase | TOWNSLEY, SARA ELIZABETH | — |
| 18253720 | METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS USING BTK INHIBITORS | SHOWALTER, ALEXANDER KEITH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263448 | METHODS OF TREATING CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION USING BTK INHIBITORS | SEITZ, ANTHONY JOSEPH | 29d |
| 18897194 | KAT6 Inhibitors | CHICKS, ASHLI ARIANA | — |
| 18748855 | SOLID FORMS OF A TYK2 INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | TOWNSLEY, SARA ELIZABETH | — |
| 18680922 | Methods of Synthesis of Chiral 3,5-Disubstituted Morpholine Compounds and Intermediates Useful Therein | CHEN, PO-CHIH | — |
| 18678898 | Compounds for the Degradation of EGFR Kinase | TOWNSLEY, SARA ELIZABETH | — |
| 18697500 | ANTI-GALECTIN-9 ANTIBODIES AND THERAPEUTIC USES THEREOF | SHUPE, ELIZABETH A | — |
| 18603755 | Pyrazolopyridinone Compounds | CHANDRAKUMAR, NIZAL S | — |
| 18513255 | ANTI-CEA ANTIBODIES AND METHODS OF USE | ALLEN, MARIANNE P | — |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 1625 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18938467 | METHODS OF TREATING MYELOID MALIGNANCIES USING BCL-2 INHIBITOR | ARCORIA, PAUL JOSEPH | — | §103 | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18897194 | KAT6 Inhibitors | CHICKS, ASHLI ARIANA | — | §102§103§112 | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18748855 | SOLID FORMS OF A TYK2 INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | TOWNSLEY, SARA ELIZABETH | — | §112 | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18680922 | Methods of Synthesis of Chiral 3,5-Disubstituted Morpholine Compounds and Intermediates Useful Therein | CHEN, PO-CHIH | — | §102 | Non-Final OA | — | Pending | May 31, 2024 |
| 18678898 | Compounds for the Degradation of EGFR Kinase | TOWNSLEY, SARA ELIZABETH | — | DP | Non-Final OA | — | Pending | May 30, 2024 |
| 18697500 | ANTI-GALECTIN-9 ANTIBODIES AND THERAPEUTIC USES THEREOF | SHUPE, ELIZABETH A | — | §103§112DP | Non-Final OA | — | Pending | Apr 01, 2024 |
| 18603755 | Pyrazolopyridinone Compounds | CHANDRAKUMAR, NIZAL S | 1625 | §112Other | Non-Final OA | — | Pending | Mar 13, 2024 |
| 18513255 | ANTI-CEA ANTIBODIES AND METHODS OF USE | ALLEN, MARIANNE P | 1647 | §102§103§112DP | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18263448 | METHODS OF TREATING CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION USING BTK INHIBITORS | SEITZ, ANTHONY JOSEPH | 1629 | §102§103 | Final Rejection | 29d | Pending | Jul 28, 2023 |
| 18253720 | METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS USING BTK INHIBITORS | SHOWALTER, ALEXANDER KEITH | 1629 | §103§112 | Final Rejection | — | Pending | May 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial